Black Diamond Therapeutics paid its 3 named executives $4.9M in total in FY2025 (Dec). CEO Mark A. Velleca, M.D., Ph.D. was paid $2.2M of that.
Pay$100 in the stock at the end of FY23 → $86
Pay of each named executive
Mark A. Velleca, M.D., Ph.D.President and Chief Executive Officer
| FY2025 (Dec) | ||||||
| FY2024 (Dec) |
2 years
Sergey Yurasov, M.D., Ph.D.Chief Medical Officer
| FY2025 (Dec) | ||||||
| FY2024 (Dec) | ||||||
| FY2023 (Dec) |
3 years
Brent Hatzis-Schoch, Esq.Chief Operating Officer and General Counsel
| FY2025 (Dec) | ||||||
| FY2024 (Dec) |
2 years
Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.